A grant from the National Institute of Neurological Disorders and Stroke, which allows for concurrent phase I and II trial design review, will speed up the development of novel treatments for patients with ALS and FTD.
Krista Rossi
Advertisement
Articles by Krista Rossi
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
Advances in Fragile X Syndrome Therapeutics: Overviewing the Pipeline
4
Investigating Codabakalner in a Phase 2b/3 Trial for the Treatment of Fragile X Syndrome: The CLARITY Study
5